Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Septerna, Inc. Common Stock

SEPN

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

Last trade $39.70
Day change -$1.97 (-4.73%)
Day range $39.38 – $42.83
Volume 117,468
Market cap $1.98B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.98B
Price / earnings
—
Price / book
4.63×
Price / sales
20.58×
EV / sales
18.85×
EV / EBITDA
-25.29×

Profitability

Earnings per share
-$1.24
Return on assets
-9.53%
Return on equity
-13.79%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
4.84×
Quick ratio
4.84×
Cash ratio
1.59×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$77.59M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SEPN, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$18.88M$26.75M$26.52M$24.12M$21.5M$119K$219K$212K
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$18.88M$26.75M$26.52M$24.12M$21.5M$119K$219K$212K
Selling, general and administrative$9.55M$8.45M$10.29M$8.28M$7.12M$6.91M$6.86M$5.61M
Research and development$36.56M$35.13M$29.54M$31.86M$24.26M$22.19M$19.27M$19.32M
Total operating expenses$46.11M$43.58M$39.82M$40.14M$31.38M$29.1M$26.13M$24.93M
Operating income-$27.23M-$16.84M-$13.3M-$16.02M-$9.89M-$28.98M-$25.91M-$24.72M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$21.97M-$12.06M-$8.3M-$10.73M$8.17M-$24.84M-$21.48M-$20.83M
Income taxes$4.62M$973K$337K$12K$0$0$0-$160K
Net income-$26.59M-$13.03M-$8.64M-$10.74M$8.17M-$24.84M-$21.48M-$20.67M
Net income attributable to common shareholders-$26.59M-$13.03M-$8.64M-$10.74M$8.17M-$24.84M-$21.48M-$20.67M
EBITDA-$26.84M-$16.41M-$12.88M-$15.62M-$9.49M-$28.57M-$25.51M-$24.33M
Basic earnings per share-$0.57-$0.29-$0.19-$0.24$0.18-$0.56-$0.49-$0.63
Diluted earnings per share-$0.57-$0.29-$0.19-$0.25$0.18-$0.56-$0.49-$0.63

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Septerna, Inc. (SEPN) Reports Q3 Loss, Lags Revenue Estimates

Septerna, Inc. (SEPN) reported a quarterly loss of $0.57 per share, missing consensus estimates of $0.55, and posted revenues of $18.88 million, falling 19.52% short of expectations. The company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revisions, with shares expected to underperform the market in the near term despite gaining 75.2% year-to-date.

Zacks Investment Research

Moderna (MRNA) Q3 Earnings and Revenues Top Estimates

Moderna reported quarterly earnings of $0.38 per share, significantly beating the consensus estimate of a loss of $1.1 per share, with a 134.55% earnings surprise. The company posted revenues of $1.31 billion, surpassing estimates by 47.73%. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. Moderna shares have gained 718.8% year-to-date, substantially outperforming the S&P 500's 7.4% gain.

Zacks Investment Research

Puma Biotech (PBYI) Tops Q3 Earnings Estimates

Puma Biotech reported Q3 2026 earnings of $0.15 per share, beating consensus estimates of $0.11 by 36.36%, but revenues of $55.1 million missed expectations by 3.54%. The company has outperformed the market by 79.7% year-to-date. With mixed estimate revisions, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market.

GlobeNewswire Inc.

Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Septerna, Inc. announced the grant of 275,000 non-qualified stock options to Dr. Rajiv Patni, the company's newly appointed Chief Medical Officer. The options have an exercise price of $37.37 per share, a ten-year term, and vest over four years with 25% vesting after one year and the remainder vesting monthly over 36 months.

GlobeNewswire Inc.

Septerna to Participate in Upcoming Investor Conferences

Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company focused on GPCR drug discovery, announced participation in two investor conferences in September 2026. The company also appointed industry veteran Rajiv Patni, M.D., as Chief Medical Officer. Septerna is advancing its Phase 1 clinical trial for SEP-479, an oral small molecule PTH1R agonist, with SAD/MAD data expected in Q1 2027.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.